
FDA Expands Dexmedetomidine for At-Home Use
Key Takeaways
- FDA authorization enables outpatient self-administration of dexmedetomidine sublingual film for acute agitation in schizophrenia, schizoaffective disorder, and bipolar I/II disorder, filling a prior absence of approved at-home oral options.
- SERENITY At-Home (12-week, double-blind, placebo-controlled) evaluated 120 mcg in 246 adults; 2628 episodes were recorded, with successful self-dosing and 81% trial completion.
For patients with schizophrenia or bipolar I or II disorder, dexmedetomidine use will no longer require provider supervision.
The FDA has approved dexmedetomidine (IGALMI®) for at-home use in the treatment of schizophrenia or bipolar disorder, according to a release.1,2
“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” said Chris Fox, executive vice president of US commercial and head of innovative franchise at Teva Pharmaceuticals. “With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it, reflecting Teva’s commitment to improving how care is experienced in everyday life.”
Prior to this regulatory decision, clinicians and patients lacked an FDA-approved oral option for self-managing acute agitation at home, leaving a major gap in outpatient psychiatric care.3,4
READ MORE:
When dexmedetomidine sublingual film first entered the market, its rapid onset of action demonstrated statistically significant separation from placebo in as little as 20 minutes during pivotal trials, offering a differentiated approach to managing debilitating symptoms. However, because the initial label was restricted to supervised administration within a 24-hour timeframe, outpatient management remained severely constrained.2-4
BioXcel Therapeutics, the original manufacturer of dexmedetomidine, entered an asset sale agreement with Teva in August of this year, essentially giving all of its assets to Teva. Then, in October, Teva officially acquired IGALMI.1,5
Clinical Evidence Supporting Outpatient Self-Administration
The approval for outpatient self-administration is backed by data from the pivotal phase 3 SERENITY At-Home trial. This 12-week, double-blind, placebo-controlled safety study evaluated the 120-microgram dose in 246 adult patients living alone or with a caregiver who experienced agitation episodes despite receiving stable baseline treatment for schizophrenia or bipolar disorder.2,6
Participants self-administered the sublingual film under the tongue or behind the lower lip upon experiencing agitation. Over the trial period, participants recorded 2628 agitation episodes, with 208 patients actively treating 2437 episodes and averaging nearly 12 treated episodes per participant.2,3,6
Trial results demonstrated strong feasibility and safety, with 81% of enrolled participants completing the 12-week evaluation. Notably, all participants were able to successfully self-administer the sublingual film, and no patients in the treatment group discontinued due to tolerability issues.2,6
The safety profile aligned with existing clinical data, revealing no treatment-related serious adverse events, syncopes, or falls, while also showing no evidence of cumulative toxicity upon repeated dosing over 12 weeks. Furthermore, exploratory efficacy analyses using a modified Clinical Global Impression-Severity scale confirmed that dexmedetomidine significantly reduced agitation compared with placebo across mild, moderate, and severe episodes, with the greatest reduction observed during severe events.
Essential Guidance for Pharmacy Practice and Patient Counseling
For community and health-system pharmacists, the expanded indication shifts dexmedetomidine into the outpatient dispensing realm, necessitating tailored patient counseling and risk management strategies.3,6
Pharmacists reviewing prescriptions for at-home dexmedetomidine must counsel patients and caregivers on proper administration, instructing them to place the film sublingually or buccally and to sit or lie down after administration to mitigate potential blood pressure changes. Because dexmedetomidine acts as a selective alpha-2 adrenergic agonist, common adverse effects include drowsiness, dizziness, dry mouth, oral paresthesia, low blood pressure, and orthostatic hypotension.3
Pharmacists should also evaluate patient medical histories for underlying cardiovascular conditions, slow heart rate, or concurrent medications that lower blood pressure or prolong the QT interval. Patients must be warned to avoid activities requiring mental alertness, such as driving or operating heavy machinery, for at least 8 hours following a dose.
By bridging hospital care and community pharmacy practice, the expanded approval enables pharmacists to play a central role in educating caregivers, optimizing outpatient psychiatric therapies, and helping reduce emergency room visits driven by acute agitation episodes.3,4,6
“IGALMI is the first new acute treatment for schizophrenia or bipolar disorder-associated agitation in nearly a decade and represents a differentiated approach to helping patients manage this difficult and debilitating symptom,” said Mehta upon dexmedetomidine’s initial approval.4
READ MORE:
REFERENCES
1. U.S. FDA approves IGALMI® as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. Teva Pharmaceuticals. News Release. November 16, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403459/0/en/u-s-fda-approves-igalmi-as-first-at-home-acute-treatment-for-agitation-associated-with-schizophrenia-schizoaffective-disorder-or-bipolar-i-or-ii-disorder-in-adults.html
2. Walters J. Ahead of the FDA action date: a timeline of Igalmi for agitation in bipolar disorder and schizophrenia. Psychiatry Live. November 13, 2026. Accessed November 13, 2026. https://www.psychiatrictimes.com/view/ahead-of-the-fda-action-date-a-timeline-of-igalmi-for-agitation-in-bipolar-disorder-and-schizophrenia
3. BioXcel Therapeutics announces Food & Drug Administration acceptance of supplemental New Drug Application for use of IGALMI® in the at-home setting. BioXcel Therapeutics. News Release. April 1, 2026. Accessed November 13, 2026. https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-food-drug-administration
4. Kuntz L. FDA approves dexmedetomidine sublingual film for acute agitation. Drug Topics. April 8, 2022. Accessed November 13, 2026. https://www.drugtopics.com/view/fda-approves-dexmedetomidine-sublingual-film-for-acute-agitation
5. BioXcel Therapeutics enters into asset sale agreement with Teva Pharmaceuticals. BioXcel Therapeutics. News Release. August 28, 2026. Accessed November 16, 2026. https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-enters-asset-sale-agreement-teva
6. Ernst D. Study supports at-home use of dexmedetomidine sublingual film for agitation episodes. September 3, 2025. Accessed November 13, 2026. https://www.psychiatryadvisor.com/news/study-supports-at-home-use-dexmedetomidine-sublingual-film-agitation-episodes/
Related to this article








